Ping‐I Hsu

5.9k total citations · 1 hit paper
145 papers, 4.3k citations indexed

About

Ping‐I Hsu is a scholar working on Surgery, Gastroenterology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ping‐I Hsu has authored 145 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Surgery, 56 papers in Gastroenterology and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ping‐I Hsu's work include Helicobacter pylori-related gastroenterology studies (69 papers), Gastroesophageal reflux and treatments (43 papers) and Gastric Cancer Management and Outcomes (28 papers). Ping‐I Hsu is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (69 papers), Gastroesophageal reflux and treatments (43 papers) and Gastric Cancer Management and Outcomes (28 papers). Ping‐I Hsu collaborates with scholars based in Taiwan, United States and South Korea. Ping‐I Hsu's co-authors include Kwok‐Hung Lai, Deng‐Chyang Wu, Wen‐Chi Chen, Gin‐Ho Lo, David Y. Graham, Chiun‐Ku Lin, Hsien‐Chung Yu, Jin‐Shiung Cheng, Feng‐Woei Tsay and Wei‐Lun Tsai and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and PLoS ONE.

In The Last Decade

Ping‐I Hsu

141 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fecal microbiota transplantation: Review and update

2018 399 citations Jiunn‐Wei Wang, Chao‐Hung Kuo et al. Journal of the Formosan Medical Association profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ping‐I Hsu Taiwan	38	2.9k	1.4k	1.1k	838	785	145	4.3k
Kwong Ming Fock Singapore	34	3.0k 1.0×	1.3k 0.9×	1.6k 1.4×	570 0.7×	241 0.3×	122	4.5k
José Marı́a Pajares Spain	31	2.4k 0.8×	1.3k 0.9×	884 0.8×	579 0.7×	371 0.5×	103	3.4k
Christian Schulz Germany	24	1.9k 0.6×	602 0.4×	733 0.6×	491 0.6×	209 0.3×	86	3.2k
Spiros D. Ladas Greece	33	2.0k 0.7×	1.3k 0.9×	829 0.7×	470 0.6×	258 0.3×	130	3.5k
M. Miglioli Italy	34	1.8k 0.6×	873 0.6×	475 0.4×	989 1.2×	387 0.5×	142	3.4k
Shailja C. Shah United States	34	2.2k 0.8×	658 0.5×	1.1k 1.0×	1.1k 1.4×	134 0.2×	140	4.4k
Fernando Fernández‐Bañares Spain	46	1.9k 0.7×	1.8k 1.3×	310 0.3×	3.5k 4.2×	410 0.5×	186	6.2k
A T Axon United Kingdom	40	3.2k 1.1×	856 0.6×	1.3k 1.2×	944 1.1×	87 0.1×	111	4.9k
Ratha‐Korn Vilaichone Thailand	24	1.6k 0.6×	493 0.3×	703 0.6×	259 0.3×	143 0.2×	130	2.2k
Pedro Pimentel‐Nunes Portugal	32	2.4k 0.8×	1.1k 0.8×	2.4k 2.1×	437 0.5×	136 0.2×	126	4.0k

Countries citing papers authored by Ping‐I Hsu

Since Specialization

Citations

This map shows the geographic impact of Ping‐I Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping‐I Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping‐I Hsu more than expected).

Fields of papers citing papers by Ping‐I Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ping‐I Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping‐I Hsu. The network helps show where Ping‐I Hsu may publish in the future.

Co-authorship network of co-authors of Ping‐I Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Ping‐I Hsu. A scholar is included among the top collaborators of Ping‐I Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ping‐I Hsu. Ping‐I Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsu, Ping‐I, Chien‐Lin Chen, Kuan-Yang Chen, et al.. (2025). Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial. The American Journal of Gastroenterology. 2 indexed citations

Hsu, Ping‐I, et al.. (2024). Sa1367 BOTH 14-DAY VONOPRAZAN TRIPLE THERAPY AND 14-DAY RABEPRAZOLE REVERSE HYBRID THERAPY ARE SUPERIOR TO 14-DAY VONOPRAZAN HIGH-DOSE DUAL THERAPY FOR THE FIRST-LINE ANTI-H. PYLORI TREATMENT IN POPULATION WITH HIGH RATES OF ANTIBIOTIC RESISTANCE. Gastroenterology. 166(5). S–431. 1 indexed citations

Chen, Chien‐Lin, Deng‐Chyang Wu, Wei‐Yi Lei, et al.. (2023). Independent Risk Factors Predicting Eradication Failure of Hybrid Therapy for the First-Line Treatment of Helicobacter pylori Infection. Microorganisms. 12(1). 6–6. 8 indexed citations

Hsu, Ping‐I, Kuan-Yang Chen, Wei‐Chen Tai, et al.. (2023). Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. The American Journal of Gastroenterology. 118(7). 1184–1195. 12 indexed citations

Hsu, Ping‐I, et al.. (2022). Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina. 58(3). 436–436. 3 indexed citations

Hsieh, Meng‐Shu, Fu‐Chen Kuo, Meng‐Chieh Wu, et al.. (2021). Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. Journal of the Formosan Medical Association. 121(8). 1450–1457. 9 indexed citations

Tu, Yu‐Kang, et al.. (2020). Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterology. 7(1). e000472–e000472. 13 indexed citations

Wang, Jiunn‐Wei, Chao‐Hung Kuo, Fu‐Chen Kuo, et al.. (2018). Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association. 118. S23–S31. 399 indexed citations breakdown →

Wang, Fuwei, et al.. (2018). The Prevalence and Risk Factors of Gastric Polyp in Asymptomatic Patients Receiving Health Examination. Gastroenterology Research and Practice. 2018. 1–7. 3 indexed citations

10.

Sun, Wei‐Chih, I-Shu Chen, Huei‐Lung Liang, et al.. (2017). Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection. Oncotarget. 8(61). 104571–104581. 27 indexed citations

11.

Hsu, Ping‐I, Sung‐Shuo Kao, Deng‐Chyang Wu, et al.. (2015). A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine. 94(48). e2104–e2104. 26 indexed citations

12.

Wu, I‐Chen, Yao‐Hsiang Shih, Meng‐Chieh Wu, et al.. (2015). Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfection. BioMed Research International. 2015. 1–6. 19 indexed citations

13.

Hsu, Ping‐I. (2015). Hybrid therapy forHelicobacter pyloriinfection: A systemic review and meta-analysis. World Journal of Gastroenterology. 21(45). 12954–12954. 36 indexed citations

14.

Chen, Wen‐Chi, Yanhua Chen, Ping‐I Hsu, et al.. (2014). Gastrointestinal Hemorrhage in Warfarin Anticoagulated Patients: Incidence, Risk Factor, Management, and Outcome. BioMed Research International. 2014. 1–7. 36 indexed citations

15.

Tsai, Tzung‐Jiun, Kwok‐Hung Lai, Ping‐I Hsu, et al.. (2012). Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. Journal of the Formosan Medical Association. 111(12). 705–710. 21 indexed citations

16.

Chen, Tai-An, Angela Chen, Gin‐Ho Lo, et al.. (2009). Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scandinavian Journal of Gastroenterology. 44(5). 619–625. 80 indexed citations

17.

Lo, Gin‐Ho, Wen‐Chi Chen, Mei‐Hsiu Chen, et al.. (2002). Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology. 123(3). 728–734. 108 indexed citations

18.

Chou, Ai‐Hsiang, Hwei-Fang Tsai, Ling-Li Lin, et al.. (2001). Enhanced Proliferation and Increased IFN-γ Production in T Cells by Signal Transduced Through TNF-Related Apoptosis-Inducing Ligand. The Journal of Immunology. 167(3). 1347–1352. 85 indexed citations

19.

Lo, Gin‐Ho, Kwok‐Hung Lai, Jin‐Shiung Cheng, et al.. (1998). The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: A prospective, randomized trial. Hepatology. 28(2). 391–395. 63 indexed citations

20.

Hsu, Ping‐I, Samuel H.H. Chan, Tsung‐Yen Chang, et al.. (1994). Bleeding peptic ulcer--risk factors for rebleeding and sequential changes in endoscopic findings.. Gut. 35(6). 746–749. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact